DK3331877T3 - Pyrazolpyrimidinderivat og anvendelser deraf - Google Patents

Pyrazolpyrimidinderivat og anvendelser deraf Download PDF

Info

Publication number
DK3331877T3
DK3331877T3 DK16753709.1T DK16753709T DK3331877T3 DK 3331877 T3 DK3331877 T3 DK 3331877T3 DK 16753709 T DK16753709 T DK 16753709T DK 3331877 T3 DK3331877 T3 DK 3331877T3
Authority
DK
Denmark
Prior art keywords
pyrimidine derivative
pyrazole pyrimidine
pyrazole
derivative
pyrimidine
Prior art date
Application number
DK16753709.1T
Other languages
Danish (da)
English (en)
Inventor
Neriah Yinon Ben
Guy Brachya
Waleed Minzel
Irit Snir-Alkalay
Joseph VACCA
Dansu Li
Ido Burstain
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Application granted granted Critical
Publication of DK3331877T3 publication Critical patent/DK3331877T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16753709.1T 2015-08-04 2016-08-04 Pyrazolpyrimidinderivat og anvendelser deraf DK3331877T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200846P 2015-08-04 2015-08-04
US201562268750P 2015-12-17 2015-12-17
PCT/IL2016/050852 WO2017021969A1 (en) 2015-08-04 2016-08-04 Pyrazole pyrimidine derivative and uses thereof

Publications (1)

Publication Number Publication Date
DK3331877T3 true DK3331877T3 (da) 2022-01-03

Family

ID=56738143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16753709.1T DK3331877T3 (da) 2015-08-04 2016-08-04 Pyrazolpyrimidinderivat og anvendelser deraf

Country Status (23)

Country Link
US (4) US10376511B2 (enExample)
EP (1) EP3331877B1 (enExample)
JP (1) JP7083309B2 (enExample)
KR (1) KR102698366B1 (enExample)
CN (1) CN108137562B (enExample)
AU (2) AU2016304464B2 (enExample)
CA (1) CA2994644A1 (enExample)
CY (1) CY1124898T1 (enExample)
DK (1) DK3331877T3 (enExample)
ES (1) ES2901349T3 (enExample)
HR (1) HRP20211949T1 (enExample)
HU (1) HUE057607T2 (enExample)
IL (1) IL257282B (enExample)
LT (1) LT3331877T (enExample)
MX (1) MX384172B (enExample)
PL (1) PL3331877T3 (enExample)
PT (1) PT3331877T (enExample)
RS (1) RS62728B1 (enExample)
RU (1) RU2735522C2 (enExample)
SI (1) SI3331877T1 (enExample)
SM (1) SMT202100720T1 (enExample)
WO (1) WO2017021969A1 (enExample)
ZA (1) ZA201800671B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376511B2 (en) * 2015-08-04 2019-08-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pyrazole pyrimidine derivative and uses thereof
MX394556B (es) * 2017-02-01 2025-03-24 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2019155468A1 (en) 2018-02-08 2019-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
TWI898556B (zh) 2018-07-13 2025-09-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
SG11202113211PA (en) * 2019-06-03 2021-12-30 Biotheryx Inc Non-hygroscopic crystalline salts of a pyrazole compound, and pharmaceutical compositions and use thereof
WO2021000957A1 (zh) * 2019-07-04 2021-01-07 北京国鸿生物医药科技有限公司 一种杂环化合物、其药物组合物及用途
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
AU2021209057A1 (en) * 2020-01-13 2022-06-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pyrazolylpyrimidines and use thereof
WO2021155050A1 (en) * 2020-01-29 2021-08-05 Biotheryx, Inc. Kinase modulators, pharmaceutical compositions, and therapeutic applications
WO2021191384A1 (en) * 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators
US20240207268A1 (en) * 2021-03-24 2024-06-27 Biotheryx, Inc. Pyrazolylpyrimidines for treating malignant solid tumor
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11752151B2 (en) * 2021-07-12 2023-09-12 Buddhist Tzu Chi Medical Foundation Method for enhancing hair growth
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2025199440A1 (en) * 2024-03-21 2025-09-25 Edgewood Oncology Methods of treating liposarcoma using a pyrazole compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343781B1 (en) 2000-12-05 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US6884804B2 (en) 2001-05-16 2005-04-26 Vertex Pharmaceuticals Incorporated Inhibitors of Src and other protein kinases
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
US20090036448A1 (en) 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
JP2007145819A (ja) 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
JP2009538352A (ja) 2006-05-26 2009-11-05 アストラゼネカ アクチボラグ 細胞増殖を阻害するための薬剤としての2−カルボシクロアミノ−4−イミダゾリルピリミジン類
EP2231636B1 (en) 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
WO2013066684A1 (en) 2011-11-04 2013-05-10 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
CA2925211A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3057956B1 (en) * 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US10376511B2 (en) 2015-08-04 2019-08-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pyrazole pyrimidine derivative and uses thereof
MX394556B (es) * 2017-02-01 2025-03-24 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
WO2019155468A1 (en) 2018-02-08 2019-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use

Also Published As

Publication number Publication date
AU2021200839A1 (en) 2021-03-04
US10960003B2 (en) 2021-03-30
EP3331877B1 (en) 2021-09-22
CY1124898T1 (el) 2023-01-05
SI3331877T1 (sl) 2022-02-28
US20180214447A1 (en) 2018-08-02
ES2901349T3 (es) 2022-03-22
MX2018001395A (es) 2018-04-13
US11925641B2 (en) 2024-03-12
PT3331877T (pt) 2021-12-27
RU2735522C2 (ru) 2020-11-03
IL257282B (en) 2021-06-30
RU2018107668A (ru) 2019-09-05
PL3331877T3 (pl) 2022-01-31
SMT202100720T1 (it) 2022-01-10
CN108137562B (zh) 2021-11-30
EP3331877A1 (en) 2018-06-13
NZ739511A (en) 2023-08-25
US20190365759A1 (en) 2019-12-05
AU2016304464B2 (en) 2020-11-19
US20250049793A1 (en) 2025-02-13
LT3331877T (lt) 2022-01-10
RS62728B1 (sr) 2022-01-31
IL257282A (en) 2018-03-29
RU2018107668A3 (enExample) 2020-01-13
KR20180043794A (ko) 2018-04-30
AU2016304464A1 (en) 2018-02-22
ZA201800671B (en) 2020-05-27
CN108137562A (zh) 2018-06-08
WO2017021969A1 (en) 2017-02-09
HRP20211949T1 (hr) 2022-03-18
KR102698366B1 (ko) 2024-08-26
JP7083309B2 (ja) 2022-06-10
MX384172B (es) 2025-03-14
JP2018525441A (ja) 2018-09-06
HK1256535A1 (en) 2019-09-27
CA2994644A1 (en) 2017-02-09
US20210251992A1 (en) 2021-08-19
HUE057607T2 (hu) 2022-06-28
US10376511B2 (en) 2019-08-13

Similar Documents

Publication Publication Date Title
DK3331877T3 (da) Pyrazolpyrimidinderivat og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
IL280863A (en) Autotaxin inhibitors and uses thereof
LT3386323T (lt) Asmeninis garinimo prietaisas
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
SI3310982T1 (sl) Pohištveni šarnir
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
IL265166B (en) Anti-influenza virus pyrimidine derivatives
IL259150B (en) Pyrimidine derivative and use thereof
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
EP3564216A4 (en) PYRIMIDINE DERIVATIVE
LT3371168T (lt) Indolin-2-ono dariniai
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3256479T3 (da) 4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DE112015003841A5 (de) Di- und triphosphat-propharmaka
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
EP3372589A4 (en) pyrimidine derivative
DK3180335T3 (da) Cytokrom-p450-inhibitorer og anvendelser deraf